Skip to main content

Restoring Testosterone in Older Men may Lower Risk of Heart Attack, Stroke, Death

 

Clinical courses

The study found Restoring testosterone in older men to normal level through gels, patches, or injections may lower their risk of heart attack, stroke, or death from any cause. The study appeared online in the European Heart Journal
Rajat Barua, assistant professor of medicine at the University of Kansas in the US, said, "It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels. Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in (heart attack) or stroke and had significantly less benefit on mortality."

The study findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart. Until now, the medical community lacks results from any definitive clinical trial that might provide clear guidance. The US Food and Drug Administration (FDA) had issued guidance earlier in 2015 advising clinicians about the over-use of testosterone therapy, and pointing to a possible increased risk of heart attack and stroke.

For the study, researchers looked at data on more than 83,000 men with documented low testosterone, all age 50 years or above, who received care between 1999 and 2014. They divided the men into three clinical groups- those who were treated to the point where their total testosterone levels returned to normal, those who were treated but without reaching normal, and those who were untreated and remained at low levels.

The sharpest contrast emerged between those who were treated and attained normal levels and those with low testosterone who went untreated. The treated men were 56% less likely to die during the follow-up period, 24% less likely to suffer a heart attack, and 36% less likely to have a stroke. The exact reasons for testosterone's apparent benefits for the heart and overall survival are not clear.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>